Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis. In this one-year, 10-subject dose escalation clinical trial, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy achieved a 90% reduction (p = 0.0039) in annualized relapse rate (ARR) in subjects who received one of the three dosage levels; the doses were 6 - 9 x 10(6), 30 - 45 x 10(6) or 60 - 90 x 10(6) attenuated T-cells. Subjects in the study received subcutaneous injections of Tovaxin over a period of 20 weeks (0, 4, 12 and 20 weeks) and were monitored for an additional 32 weeks.

The safety profile for all dosage levels revealed no severe adverse reactions related to T-cell vaccination. With increasing dosage, an increase in mild injection site reactions was observed and these resolved within 48 hours.

All subjects currently are enrolled in an extension study to collect longitudinal safety and effectiveness data.

David McWilliams, president and chief executive officer of Opexa, commented, "We are particularly encouraged by the data from this dose escalation trial. While all three dosage levels were safe and effective, the group treated with the 30 - 45 x 10(6) T-cell dose achieved a 100% reduction in ARR. The currently enrolling Tovaxin IIb clinical trial is being conducted with the 30 - 45 x 10(6) T-cell dose."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T- cell vaccination with clinically isolated syndrome (CIS
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:3/18/2010)... an international biopharmaceutical company with,operations in the U.S. and China , is pleased to announce the exercise of a,warrant by a principal shareholder, RimAsia Capital Partners, LP ... ... ... ...
(Date:3/18/2010)... HARBIN, China , March 18 /PRNewswire-Asia-FirstCall/ ... Medical" or "the Company") (Nasdaq: CSKI ), ... the People,s Republic of China ("PRC"), ... drug co-developed by Taiwan,Golden Biotechnology Corporation ("Golden Biotech") ...
(Date:3/17/2010)... March 17, 2010 the FDA gave approval to Envoy ... restoration device. The approval follows a December 18, 2009 ... favor of approving the Esteem® for moderate to severe sensorineural hearing ... believe the Esteem® "represents a breakthrough technology." , ...
Breaking Medicine Technology:NeoStem Announces Warrant Exercise by Principal Shareholder 2NeoStem Announces Warrant Exercise by Principal Shareholder 3NeoStem Announces Warrant Exercise by Principal Shareholder 4NeoStem Announces Warrant Exercise by Principal Shareholder 5China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 2China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 3China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 4China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 5FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device 2Eliminate Cost Sharing for Medicaid Preventive Services Partnership Urges House Committee 53259 1Eliminate Cost Sharing for Medicaid Preventive Services Partnership Urges House Committee 53259 2Spleen May Help Heart Recover From Disease 53256 1Spleen May Help Heart Recover From Disease 53256 2Americans Spent 2433 9 Billion Out of Pocket on Complementary and Alternative Medicine 53254 1Americans Spent 2433 9 Billion Out of Pocket on Complementary and Alternative Medicine 53254 2Americans Spent 2433 9 Billion Out of Pocket on Complementary and Alternative Medicine 53254 3Americans Spent 2433 9 Billion Out of Pocket on Complementary and Alternative Medicine 53254 4
... DIEGO, April 30 SpectraScience, Inc. (OTC Bulletin Board: ... that Iowa,s Des Moines Register published an article reporting that its ... at the University of Iowa . Since Last July, ... Iowa have used the LUMA Cervical Imaging System in ...
... Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer ... cure, announced today that it is developing a microarray-based ... The Arrayit test will allow researchers and clinicians to ... and livestock and to distinguish the threatening mutated strain ...
Other Medicine Technology:Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 2Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 3Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip 2Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip 3
(Date:3/21/2010)... March 21 Family Research Council President Tony Perkins released the following statement in response to reports that President Obama may ... ... , , ... ... ...
(Date:3/21/2010)... in humans, scientists used RNA to stop production ... (HealthDay News) -- For the first time in ... to enter tumor cells and block the production ... report. , "They,re basically putting an instruction ... this protein expressed for now," explained Gregory Adams, ...
(Date:3/18/2010)... ... , ... -- This Mother’s Day, Save the Children has a special gift for your mom that ... For as little as $13 you can buy, in your own mother’s name, one Newborn ...
(Date:3/18/2010)... General anesthesia just ... Southeast Texas provides their patients with a more suitable option called TIVA. , ... Houston, TX (PRWEB) March 18, 2010 -- ... the top concerns for people considering plastic surgery. TIVA, or Total Intravenous Anesthesia, then, is ...
(Date:3/18/2010)... ... ... ... WASHINGTON , March 18 Kids in Minnesota will take center stage in the fight against tobacco on March 24 as they join thousands ...
Breaking Medicine News(10 mins):Health News:Executive Order Will In No Way Prevent Federal Funding of Elective Abortion 2Health News:Executive Order Will In No Way Prevent Federal Funding of Elective Abortion 3Health News:Executive Order Will In No Way Prevent Federal Funding of Elective Abortion 4Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 2Health News:Gene-Targeted Cancer Fix Could Be a Breakthrough 3Health News:A Mother's Day Gift that Gives Lasting Joy 2Health News:Plastic Surgery Institute of Southeast Texas Offers Milder Anesthesia for Outpatient Procedures 2Health News:Minnesota Kids 'Kick Butts' on March 24 2Health News:Minnesota Kids 'Kick Butts' on March 24 3Health News:Minnesota Kids 'Kick Butts' on March 24 4Health News:Minnesota Kids 'Kick Butts' on March 24 5
... July 2 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... services and Western healthcare products in the People,s,Republic ... long-awaited,approval from the State Food and Drug Administration ... new products, including the daVinci S,Surgical System manufactured ...
... raise cardiovascular risks, , , WEDNESDAY, July 2 (HealthDay News) ... be subjected to more thorough safety reviews to ensure ... Food and Drug Administration advisers said Wednesday. , The ... of a two-day meeting, to recommend that all makers ...
... today,s,announcement that Attorney General Mike Cox is filing suit ... for a Fair and,Competitive Insurance Market is calling on ... Blue Shield of Michigan (BCBSM) to use their,unfair monopoly ... "We were confident when we raised this issue ...
... closed, American cardiologists say , , WEDNESDAY, July 2 (HealthDay ... to adrenaline did not improve survival among people who ... American cardiologists said the finding does not rule out ... report comes from a group, primarily French, that several ...
... Department of Orthopaedic Surgery at the University of Pittsburgh School of ... Center (UPMC) for Sports Medicine will be installed as the 37th ... Saturday, July 12, 2008, during the Society,s Annual Meeting in Orlando, ... ...
... of,America, Inc. announced the formation of ROSA of ... outpatient radiation oncology services. ROSA,of North Dallas is ... of America, and some of the former owners ... will own and operate Northpoint,Cancer Center in Dallas, ...
Other Medicine News:Health News:Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S 2Health News:Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S 3Health News:FDA Panel Calls for More Testing of Diabetes Drugs 2Health News:FDA Panel Calls for More Testing of Diabetes Drugs 3Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 2Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
The TS100-F trinocular model comes with a photo port that accepts Nikon's FX-III series photomicrographic systems, CCTV camera, or digital camera....
... standard laboratory microscope whose superior ... combine to make it the ... is designed to fit the ... user to fit the microscope. ...
... charts incorporate the slight change in the ... Sloan letters derived from the best corrected ... the ETDRS study. The original charts difficulty ... 234 eyes. In addition to the revised ...
Medicine Products: